SFX by Ex Libris Inc.

Title:	Associations of Killer Cell Immunoglobulin-Like Receptor Genes with Rheumatoid Arthritis
Source:	Disease Markers [0278-0240] Ramírez-De los Santos, S. yr:2012

Basic

Full text

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	De Hert, M. "Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis." CNS drugs 26.9 (2012): 733-759.
description	2.	Mitchell, Alex J. "Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders--A Systematic Review and Meta-Analysis." Schizophrenia bulletin 39.2 (2011): 306-318.
description	3.	De Hert, M. "Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices." Psychological Medicine 42.1 (2011): 1-23.
description	4.	Jones, S J. "Tumor necrosis factor." Lancet 345.8950 (1995): 648-649.
description	5.	Yeragani, V K. "Increased serum total cholesterol to HDL-cholesterol ratio after imipramine." Psychiatry Research (1990): 207-209.
description	6.	Correll, Melissa U. "Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials." Bipolar disorders 12.2 (2010): 116-141.
description	7.	Dabke, K. "The gut microbiome and metabolic syndrome." Journal of Clinical Investigation 129.10 (2019): 4050-4057.
description	8.	Bora, E. "The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis." Psychological Medicine 47.6 (2017): 1030-1040.
description	9.	Reynolds, Gavin P. "Metabolic side effects of antipsychotic drug-Pharmacological mechanisms." Pharmacology & therapeutics 125.1 (2009): 169-179.
description	10.	De Hert, M. "Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: Systematic evaluation." British journal of psychiatry 199.2 (2011): 99-105.
description	11.	De Hert, M. "Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC." European psychiatry 24.6 (2009): 412-424.
description	12.	Newcomer, John W W. "Antipsychotic medications: metabolic and cardiovascular risk." The Journal of clinical psychiatry 68.4 (2007): 8-13.
description	13.	De Hert, M. "Metabolic syndrome in people with schizophrenia: a review." World psychiatry 8.1 (2009): 15-22.
description	14.	Meyer, S M M. "The metabolic syndrome and schizophrenia." Acta psychiatrica Scandinavica 119.1 (2009): 4-14.
description	15.	KOWATCH, Robert A. "Treatment Guidelines for Children and Adolescents With Bipolar Disorder." Journal of the American Academy of Child & Adolescent Psychiatry 44.3 (2005): 213-235.
description	16.	Chong, B H. "Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion." Australian and New Zealand journal of ophthalmology (1996): 199-205.
description	17.	Westlund KN, Karin N. "Chronic inflammation and pain in a tumor necrosis factor receptor (TNFR) (p55/p75-/-) dual deficient murine model." Translational Research 160.1 (2012): 84-94.
description	18.	Bell, E. "Targeting TNF.(INFLAMMATION)(tumor necrosis factors)." Nature reviews. Immunology 9.6 (2009).
description	19.	Gandolfo, S. "Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus." The Journal of investigative dermatology 122.1 (2004): 87-94.
description	20.	Cohen, Lee S S. "Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation." The American journal of psychiatry 164.12 (2008): 1817-24.